INHIBRX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.56 USD | -1.31% |
|
-10.14% | -64.32% |
| Jun. 04 | Inhibrx Biosciences Insider Bought Shares Worth $4,927,580, According to a Recent SEC Filing | MT |
| May. 31 | Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Biotechnology Select Industry Index | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 1,243 | 1,657 | 1,073 | 1,797 |
| Enterprise Value (EV) 1 | 1,152 | 1,603 | 1,006 | 1,729 |
| P/E ratio | -10.9 x | -20.3 x | -6.8 x | -7.42 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 96.5 x | 229 x | 490 x | 998 x |
| EV / Revenue | 89.4 x | 222 x | 459 x | 961 x |
| EV / EBITDA | -17.3 x | -21.3 x | -7.87 x | -7.93 x |
| EV / FCF | -59 x | -33.4 x | -16.4 x | -15.3 x |
| FCF Yield | -1.7% | -3% | -6.11% | -6.53% |
| Price to Book | 16.5 x | 32.5 x | 18.5 x | 41.4 x |
| Nbr of stocks (in thousands) | 37,712 | 37,955 | 43,551 | 47,291 |
| Reference price 2 | 32.97 | 43.67 | 24.64 | 38.00 |
| Announcement Date | 3/12/21 | 2/28/22 | 3/6/23 | 2/28/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 8.595 | 13.21 | 12.89 | 7.231 | 2.192 | 1.8 |
| EBITDA 1 | -28.84 | -39.79 | -66.42 | -75.37 | -127.9 | -218 |
| EBIT 1 | -29.51 | -40.95 | -67.44 | -76.56 | -129.1 | -219.2 |
| Operating Margin | -343.37% | -309.99% | -523.3% | -1,058.83% | -5,890.37% | -12,178.94% |
| Earnings before Tax (EBT) 1 | -30.92 | -50.5 | -76.12 | -81.77 | -145.2 | -241.4 |
| Net income 1 | -31.16 | -51.4 | -76.12 | -81.77 | -145.2 | -241.4 |
| Net margin | -362.57% | -389.07% | -590.66% | -1,130.8% | -6,625.27% | -13,408.94% |
| EPS 2 | -1.717 | -2.831 | -3.013 | -2.151 | -3.621 | -5.121 |
| Free Cash Flow 1 | -12.2 | -12.4 | -19.54 | -48.04 | -61.52 | -112.8 |
| FCF margin | -141.99% | -93.86% | -151.6% | -664.41% | -2,806.64% | -6,269.06% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 2/22/19 | 7/28/20 | 3/12/21 | 2/28/22 | 3/6/23 | 2/28/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 7.39 | 30.2 | - | - | - | - |
| Net Cash position 1 | - | - | 91.2 | 54.1 | 66.8 | 67.8 |
| Leverage (Debt/EBITDA) | -0.2563 x | -0.7588 x | - | - | - | - |
| Free Cash Flow 1 | -12.2 | -12.4 | -19.5 | -48 | -61.5 | -113 |
| ROE (net income / shareholders' equity) | 540% | 233% | -368% | -128% | -263% | -475% |
| ROA (Net income/ Total Assets) | -135% | -140% | -49.5% | -32.5% | -36.6% | -45.8% |
| Assets 1 | 23 | 36.62 | 153.7 | 251.3 | 397.1 | 527.4 |
| Book Value Per Share 2 | -3.180 | -5.150 | 2.000 | 1.340 | 1.330 | 0.9200 |
| Cash Flow per Share 2 | 0.1200 | 0.6400 | 3.410 | 3.370 | 6.290 | 5.870 |
| Capex 1 | 1.43 | 1.81 | 1.36 | 0.86 | 0.69 | 4.59 |
| Capex / Sales | 16.63% | 13.7% | 10.58% | 11.95% | 31.3% | 255.17% |
| Announcement Date | 2/22/19 | 7/28/20 | 3/12/21 | 2/28/22 | 3/6/23 | 2/28/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -64.32% | 1.79B | |
| +16.44% | 122B | |
| +18.94% | 114B | |
| +19.62% | 25.71B | |
| -25.37% | 19.02B | |
| -20.21% | 15.83B | |
| -20.20% | 15.32B | |
| -47.37% | 14.88B | |
| +59.91% | 14.82B | |
| +4.35% | 14.1B |
- Stock Market
- Equities
- INBX Stock
- Financials Inhibrx, Inc.
